Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 5 months from now) | |
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) |
Vemlidy is owned by Gilead Sciences Inc.
Vemlidy contains Tenofovir Alafenamide Fumarate.
Vemlidy has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Vemlidy are:
Vemlidy was authorised for market use on 10 November, 2016.
Vemlidy is available in tablet;oral dosage forms.
Vemlidy can be used as treatment of chronic hepatitis b in adult patients, treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older.
Drug patent challenges can be filed against Vemlidy from 06 November, 2019.
The generics of Vemlidy are possible to be released after 15 February, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Oct 17, 2025 |
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
M(M-255) | Feb 04, 2023 |
M(M-266) | Aug 22, 2023 |
New Product(NP) | Nov 11, 2019 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older
Dosage: TABLET;ORAL